

**Adult CIRB - Early Phase Emphasis Meeting Agenda**

**July 5, 2022**

---

**I Continuing Review**

**10126**, A Pilot Phase I Study of Atezolizumab (MPDL3280A) in Combination with Immunogenic Chemotherapy (Gemcitabine-Oxaliplatin) and Rituximab for Transformed Diffuse Large B-Cell Lymphoma (Protocol Version Date 05/14/21)

---

**II Continuing Review**

**10184**, Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (Protocol Version Date 12/22/21)

---

**III Continuing Review**

**10276**, A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies (Protocol Version Date 12/09/21)

---

**IV New Study - Initial Review**

**10525**, A Phase 1b Trial of ZEN003694 (ZEN-3694) with Pembrolizumab and Nab-Paclitaxel in Patients with Metastatic Triple-Negative Breast Cancer (Protocol Version Date 05/09/22)

---